D. Marcoux, Jashin J. Wu, B. Shumel, Y. Ohya, A. Zhang, Zhen Chen
{"title":"来自LIBERTY AD PEDS 3期试验的结果:Dupilumab耐受性良好,可显著改善≥6岁至< 12岁儿童的特应性皮炎","authors":"D. Marcoux, Jashin J. Wu, B. Shumel, Y. Ohya, A. Zhang, Zhen Chen","doi":"10.1542/PEDS.147.3_MEETINGABSTRACT.300","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":228253,"journal":{"name":"Section on Advances in Therapeutics and Technology Program","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial\",\"authors\":\"D. Marcoux, Jashin J. Wu, B. Shumel, Y. Ohya, A. Zhang, Zhen Chen\",\"doi\":\"10.1542/PEDS.147.3_MEETINGABSTRACT.300\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":228253,\"journal\":{\"name\":\"Section on Advances in Therapeutics and Technology Program\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section on Advances in Therapeutics and Technology Program\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1542/PEDS.147.3_MEETINGABSTRACT.300\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section on Advances in Therapeutics and Technology Program","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1542/PEDS.147.3_MEETINGABSTRACT.300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial